Finasteride 5 mg and sexual side effects: How many of these are related to a Nocebo phenomenon?

Journal of Sexual Medicine

Volumn 4, Issue 6, 2007, Pages 1708-1712

  Mondaini, Nicola ^a   Gontero, Paolo ^b   Giubilei, Gianluca ^a   Lombardi, Giuseppe ^a   Cai, Tommaso ^a   Gavazzi, Andrea ^a   Bartoletti, Riccardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

BPH; Decreased Libido; Erectile Dysfunction; Finasteride; LUTS; Sildenafil

Indexed keywords

FINASTERIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FUNCTIONAL ASSESSMENT; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SEXUALITY;

EID: 35448960827     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00563.x     Document Type: Article

References (19)

1. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 824-37.
2. Costabile RA, Steers WD. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006; 3: 676-81.
3. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006; 97 (2 suppl): 34-8, discussion 44-5.
4. Kassabian VS. Sexual function in patients treated for being prostatic hyperplasia. Lancet 2003; 361: 60-2.
5. Finn DA, Beadles Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, Wiren KM. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev 2006; 12: 53-76.
6. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24.
7. Wessells H, Roy J, Bannow J, Grayhack J, Matsumo AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA, Waldstreicher J. Incidence and severity of sexual adverse experiences in finasteride and placebo treated men with benign prostatic hyperplasia. Urology 2003; 61: 579-84.
8. Tosti A, Pazzaglia M, Soli M, Rossi A, Rebora A, Atzori L, Barbareschi M, Benci M, Voudouris S, Vena GA. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol 2004; 140: 857-8.
9. Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (permixon), tamsulosin or finasteride. Eur Urol 2005; 48: 269-76.
10. Silvestri A, Galetta P, Cerquetani E, Marazzi G, Patrizi R, Fini M, Rosano GMC. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effect and is reversed by placebo. Eur Heart J 2003; 24: 1928-32.
11. Rosen RC, Riley A, Wagner G. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822.
12. Marquis P, Marrel A. Reproducibility and clinical and concurrent validity of the MSF-4: A four-item male sexual function questionnaire for patients with benign prostatic hyperplasia. Value Health 2001; 4: 335-43.
13. Kaplan SA. Reproducibility and clinical and concurrent validity of the MSF-4: A four-item male sexual function questionnaire for patients with benign prostatic hyperplasia. J Urol 2002; 168: 1661-2.
14. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662-7.
15. El Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors. J Sex Med 2006; 3: 144-9.
16. Hahn RA. The nocebo phenomenon: Concept, evidence, and implications for public health. Prev Med 1997; 26: 607-11.
17. Montorsi F, Padma-Nathan H, Glina S. Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra). Urology 2006; 68 (3 suppl): 26-37.
18. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. J Am Med Assoc 2002; 287: 622-7.
19. Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: Unraveling the mechanisms of the nocebo effect. Neuroscience 2007; 147: 260-71.